Table 2.
Evaluation of lorcaserin efficacy in cocaine use disorder
| Population | Outcome (last 3 weeks of treatment) | Placebo n (%) | Lorcaserin n (%) | p-value |
|---|---|---|---|---|
| Efficacy Populationa | Cocaine-Abstinent | 4/92 (4.3%) | 1/91 (1.1%) | 0.368 |
| Not Abstinent | 88/92 (95.7%) | 90/91 (98.9%) | ||
| Subset of Efficacy Population Attempting Alcohol Abstinence or Nondrinkersb |
Cocaine-Abstinent | 3/45 (6.7%) | 0/49 (0.0%) | 0.106 |
| Not Abstinent | 42/45 (93.3%) | 49/49 (100%) | ||
| All Randomized Participants | Cocaine-Abstinent | 7/124 (5.6%) | 3/118 (2.5%) | 0.225 |
| Not Abstinent | 117/124 (94.4%) | 115/118 (97.5%) |
a
Evaluation in this population constitutes the trial’s primary efficacy endpoint.
b
Evaluation in this population constitutes the secondary efficacy endpoint.